Share

EORTC at ESMO 2017 in Madrid

EORTC, in collaboration with ESMO and EACR, will present a session on tumours with rare oncogenic lesions: From pre-clinical to clinical validation on 10 September from 11:00 to 12:30.

Professor Françoise Meunier, Director of Special Projects at EORTC, will co-chair the Hans Keulen Memorial debate on Lost in rehabilitation on 11 September from 13:00 to 14:30; and Ms Anastassia Negrouk, Head of International Policy Office, will be a speaker at the Challenge Your Expert (CYE) session on the new EU clinical trials and data protection regulations. This session will take place on 11 September at 08:00.

EORTC will also be presenting three oral abstract session and five abstracts in poster sessions at ESMO (September 8-12, 2017) in Madrid.

Oral presentations

  • Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial (Abstract LBA55)

Session: Sarcoma
Time: Saturday September 9, 11:00 to 12:30
Location: Granada Auditorium
Speaker: P.G. Casali

  • Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) (Abstract LBA35)

Session: Genitourinary tumours, non-prostate
Time: Saturday September 9, 9:15 to 10:45
Location: Madrid Auditorium
Speaker: A. Bex

  • Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from the EORTC 10041/BIG 3-04 (MINDACT) trial (Abstract 150O)

Session: Breast cancer, early stage
Time: Friday September 8, 14:00 to 15:30
Location: Pamplona Auditorium
Speaker: K. Tryfonidis

Poster sessions

  • EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective clinical trials: clinical profile and response to systemic therapy (Abstract 1496P)

Session: Poster Display session
Time: Monday September 11, 13:15 to 14:15
Location: Hall 8
Authors: Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, Gronchi A

  • Evolution in Neutrophil-to-lymphocyte ratio (NLR) among advanced Soft Tissue Sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials (Abstract 1502P)

Session: Poster Display session
Time: Monday September 11, 13:15 to 14:15
Location: Hall 8
Authors: De Maio E, Touati N, Litière S, Sleijfer S, van der Graaf WT, Le Cesne A, D’Ambrosio L, Casali PG, Italiano A, Desar I, Gronchi A

  • Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (Abstract 1106TIP)

Session: Poster Display session
Time: Sunday September 10, 13:15 to 14:15
Location: Hall 8
Authors: L.Locati, C.Caballero, C. Fortpied, F. Perrone, S. Pilotti, K.J. Harrington, V. Gregoire, L. Licitra

  • Diagnostic and therapeutic strategies for elderly patients with advanced Non-Small cell lung cancer (NSCLC): results from an EORTC pan-european survey (Abstract 1371P)

Session: Poster Display session
Time: Saturday September 9, 13:15 to 14:15
Location: Hall 8
Authors: M. Giaj Levra, J. Menis, A. Luciani, E. De Maio, B. Hasan, T. Berghmans, M.A. Messiani, M. De Waele, A.-M. Dingemans, J. Donckele, C. Faivre-Finn, N. Girard, L. Greillier, S. Lantuéjoul, M. O’Brien, M. Reck, K. Tryfonidis, H. Wildiers, B. Besse, S. Novello

  • Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU): Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey (Abstract 1372P)

Session: Poster Display session
Time: Saturday September 9, 13:15 to 14:15
Location: Hall 8
Authors: Antonin Levy, Corinne Faivre-Finn, Baktiar Hasan, Eleonora De Maio, Anna S. Berghof, Anne-Marie Dingemans, Silvia Novello, Thierry Berghmans, Benjamin Besse, Lizza Hendriks

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023